Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase IV

Natural history/Epidemiology, Treatment

Enrolling by invitation

Not specified

Pharmaceutical / Industry

A6181146
NCT00444795

Trial Description

Summary

To monitor use in real practice including adverse events and efficacy on Sutene capsules(Sunitinib malate)

Further Study Information

All the patients prescribed according to approved indications at contracted institutions

Eligibility Criteria

Inclusion Criteria:

Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate or advanced renal cell carcinoma (aRCC) will be included in the study.

Exclusion Criteria:

Any patient who doesn't agree that Pfizer and companies working with Pfizer use his/her information will be excluded.

Patients with hypersensitivity to sunitinib malate or to any other component of Sutent

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00444795
Information obtained from ClinicalTrials.gov on September 26, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.